ENLV

Enlivex Ltd. Ordinary Shares (ENLV)

Stock · NASDAQ · Health Care

$0.2073as of 10/16/2026

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 2, 2026

ENLV observed as market watches S&P 500 direction. A recent Benzinga piece discussed whether the S&P 500 will open higher or lower. While the article does not mention ENLV directly, the broader market outlook can affect sentiment for small‑cap stocks like ENLV. The stock is currently showing a very low RSI, indicating oversold conditions. Investors may note the general market tone alongside the stock’s own price action.

Active signals

High Beta27.6%
200 SMA Touch0.0%
Resistance level
$0.394488
Industry
Biotechnology: Pharmaceutical Preparations

What ENLV's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Bollinger Band Breakdown20+3.6%55%
Bollinger Band Breakout20-5.9%25%
Volume Spike17-23.9%12%
200-Day Moving Average TouchActive now9-10.1%11%
Any 20-session window (baseline)-5.0%38%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About ENLV

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
34

Fundamentals

1-day range
$0.211$0.2358
Market cap
$33.33M
P/E (trailing)
0.00
P/E (forward)
-0.29
EPS (trailing)
$149.75
Dividend yield
—
Beta
1.49
Avg. volume
1.02M
Dividend pay date
March 6, 2019
52-week range
$0.21$27.15

Forecasts

1 analyst ratings

Buy 86%
Hold 14%
Sell 0%
1-year price forecast
High
$80
+38491.4%
Median
$80
+38491.4%
Low
$80
+38491.4%

Enlivex Ltd. Ordinary Shares Competitors

Chosen by industry and closest market cap.

  • ENLV
    Enlivex Ltd. Ordinary Shares
    $0.205
    ▼ 8.48%
    Market cap $33.33MP/E 0.00
    $0.21$27.15
  • LITS
    Lite Strategy Inc. Common Stock
    $1.15
    ▼ 4.17%
    Market cap $31.61MP/E —
    $0.6888$2.26
  • QUCY
    Quantum Cyber N.V. Ordinary Shares
    $1.06
    ▼ 2.75%
    Market cap $31.42MP/E —
    $0.3$4.93
  • SER
    Serina Therapeutics Inc. Common Stock
    $1.72
    ▼ 3.91%
    Market cap $35.24MP/E —
    $1.22$5.29
  • UPC
    Universe Pharmaceuticals Inc. Class A Ordinary Shares
    $3.93
    ▼ 5.30%
    Market cap $31.35MP/E —
    $2$17.96
  • LTRN
    Lantern Pharma Inc. Common Stock
    $0.668
    ▲ 0.15%
    Market cap $35.47MP/E —
    $0.651$4.58
  • NNVC
    NanoViricides Inc. Common Stock
    $1.38
    ▲ 0.73%
    Market cap $35.56MP/E —
    $0.85$2.23

P/E shows — for peers not currently carrying a live signal of their own.

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.